Corient Private Wealth LLC Purchases Shares of 201,717 Celldex Therapeutics, Inc. $CLDX

Corient Private Wealth LLC acquired a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 201,717 shares of the biopharmaceutical company’s stock, valued at approximately $4,105,000. Corient Private Wealth LLC owned about 0.30% of Celldex Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Mirador Capital Partners LP boosted its position in shares of Celldex Therapeutics by 24.1% in the second quarter. Mirador Capital Partners LP now owns 158,717 shares of the biopharmaceutical company’s stock valued at $3,230,000 after acquiring an additional 30,843 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Celldex Therapeutics in the 2nd quarter worth about $1,188,000. Sovran Advisors LLC bought a new stake in Celldex Therapeutics in the 2nd quarter valued at about $842,000. American Century Companies Inc. boosted its holdings in Celldex Therapeutics by 24.7% in the 2nd quarter. American Century Companies Inc. now owns 779,985 shares of the biopharmaceutical company’s stock valued at $15,873,000 after purchasing an additional 154,664 shares during the period. Finally, TFG Asset Management GP Ltd grew its position in shares of Celldex Therapeutics by 21.1% during the 2nd quarter. TFG Asset Management GP Ltd now owns 316,150 shares of the biopharmaceutical company’s stock worth $6,434,000 after purchasing an additional 55,150 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts recently issued reports on CLDX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, October 8th. Canaccord Genuity Group reissued a “buy” rating and set a $62.00 target price on shares of Celldex Therapeutics in a report on Wednesday, September 17th. Barclays boosted their price target on Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a research note on Wednesday. Finally, Mizuho initiated coverage on shares of Celldex Therapeutics in a research note on Tuesday, October 21st. They set an “outperform” rating and a $48.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $44.10.

Insider Transactions at Celldex Therapeutics

In other Celldex Therapeutics news, insider Richard M. Wright sold 49,298 shares of the stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $24.00, for a total value of $1,183,152.00. Following the completion of the transaction, the insider directly owned 20,833 shares in the company, valued at approximately $499,992. This trade represents a 70.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.40% of the stock is currently owned by insiders.

Celldex Therapeutics Price Performance

Shares of NASDAQ:CLDX opened at $25.60 on Friday. Celldex Therapeutics, Inc. has a one year low of $14.40 and a one year high of $30.50. The company has a market cap of $1.70 billion, a price-to-earnings ratio of -7.57 and a beta of 1.13. The firm has a 50 day simple moving average of $26.28 and a 200 day simple moving average of $24.09.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative return on equity of 33.22% and a negative net margin of 3,446.88%. As a group, analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.